Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 19,594 shares, a drop of 54.7% from the December 31st total of 43,229 shares. Approximately 3.2% of the shares of the company are short sold. Based on an average daily volume of 107,054 shares, the short-interest ratio is currently 0.2 days. Based on an average daily volume of 107,054 shares, the short-interest ratio is currently 0.2 days. Approximately 3.2% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Several research firms recently commented on BDRX. Wall Street Zen upgraded Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Biodexa Pharmaceuticals currently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

Shares of Biodexa Pharmaceuticals stock traded down $0.07 on Friday, hitting $1.77. 127,936 shares of the company’s stock traded hands, compared to its average volume of 317,944. Biodexa Pharmaceuticals has a one year low of $1.71 and a one year high of $92.00. The firm’s 50-day moving average price is $3.44 and its two-hundred day moving average price is $5.60.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.